Japan, Jan. 15 -- TEIJIN PHARMA LTD has got intellectual property rights for 'ANTI-IGF-I RECEPTOR ANTIBODY.' Other related details are as follows:
Application Number: JP,2021-096162
Category (FI): A01K67/027,A01K67/0278,A61K38/22,A61K38/25,A61K38/27,A61K38/28,A61K38/30,A61K39/395@D,A61K39/395@N,A61K45/00,A61K48/00,A61P1/04,A61P1/12,A61P1/16,A61P13/12,A61P15/00,171,A61P15/14,173,A61P17/02,A61P17/06,A61P19/08,A61P19/10,A61P21/00,A61P21/04,A61P25/00,A61P27/02,A61P27/16,A61P3/00,A61P3/00,171,A61P3/04,A61P3/10,A61P31/18,A61P35/00,A61P35/02,A61P37/02,A61P37/04,A61P43/00,111,A61P43/00,121,A61P5/00,A61P5/02,A61P5/14,A61P9/00,A61P9/10,C07K16/28,C12N1/15,C12N1/19,C12N1/21,C12N15/13,C12N15/63@Z,C12N5/071,C12N5/10,C12P21/08
Stage: Grant (IP right document published.)
Filing Date: June 8, 2021
Publication Date: Oct. 14, 2021
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
